The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2023

Filed:

Jan. 26, 2018
Applicant:

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US);

Inventors:

Xinle Cui, Gaithersburg, MD (US);

Clifford M. Snapper, Potomac, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61P 31/22 (2006.01); A61K 39/245 (2006.01); A61K 39/25 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/245 (2013.01); A61K 39/25 (2013.01); A61P 31/22 (2018.01); C12N 7/00 (2013.01); C12N 2710/16034 (2013.01); C12N 2710/16071 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16171 (2013.01); C12N 2710/16234 (2013.01); C12N 2710/16271 (2013.01); C12N 2710/16334 (2013.01); C12N 2710/16371 (2013.01); C12N 2710/16634 (2013.01); C12N 2710/16671 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/16771 (2013.01);
Abstract

Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.


Find Patent Forward Citations

Loading…